Clinical Trials
25 trialsBortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation
Massachusetts General Hospital
Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias
Thomas Jefferson University
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
Sumitomo Pharma America, Inc.
TEAM
University Hospital Heidelberg
Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia
University of California, Davis
Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer
Swiss Cancer Institute
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
National Heart, Lung, and Blood Institute (NHLBI)
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS
Dartmouth-Hitchcock Medical Center
Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype
Indiana University
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia
National Cancer Institute (NCI)
Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
Ohio State University Comprehensive Cancer Center
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome
Virginia Commonwealth University
Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
Case Comprehensive Cancer Center
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
National Cancer Institute (NCI)
Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
PS-341 in Treating Patients With Hematologic Cancer
Memorial Sloan Kettering Cancer Center
Velcaflagida in Relapsed or Refractary Acute Myeloid Leukemia
PETHEMA Foundation
PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome
National Cancer Institute (NCI)
Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML
University of Kentucky
VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia
Massachusetts General Hospital